Aethlon Medical (NASDAQ: AEMD) stock soared during intraday trading Thursday after the company revealed plans to begin Phase 1 trials for Hemopurifier® in cancer treatment.
Aethlon Medical has provided a comprehensive update on its planned phase 1 clinical trial for the Hemopurifier®, targeting patients with solid tumors who exhibit stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
Dr. Steven LaRosa, Chief Medical Officer of Aethlon Medical, emphasized the company’s progress in preparing for the upcoming clinical trials in Australia and India. He stated,
“We continue to make progress preparing for our planned, safety, feasibility, and ‘dose-finding’ oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update.”
In early May, Aethlon Medical unveiled promising new data demonstrating the successful removal of exosomes from cancer patient plasma using a miniature version of the Hemopurifier®. This breakthrough data has been promptly integrated into the required documentation for Ethics Committees at potential clinical sites.
On May 17, 2024, the company submitted these documents to the Contract Research Organizations overseeing the planned clinical trials. A potential site later submitted the documents to its Ethics Board on May 24, 2024. Additional sites in Australia and India are currently finalizing their submission packages for their respective Ethics Committees.
Upon receipt of anticipated Ethics Committee approvals, Aethlon Medical will proceed to finalize the Clinical Trial Agreements, paving the way for hospitals to commence patient recruitment for the trials. It is essential to note that the target patient population for these safety, feasibility, and dose-finding trials comprises oncology patients with solid tumors who have not responded adequately to anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
Aethlon Medical (NASDAQ: AEMD) Stock Movement
On Thursday, AEMD stock jumped 25.42%, closing at $0.55, marking a 37.53% increase for the week. The trading volume was 95,686,672 shares, significantly higher than the average daily volume of 2.65 million.
